AI Insight
Researchers developed and validated a simplified blood test to distinguish between mpox virus infection and vaccination by testing individual viral antigens and antigen combinations. The study identified that the combination of two specific antigens (A35R and B6R) achieved diagnostic accuracy nearly equivalent to a more complex six-antigen test, with an area under the curve of 0.93. Individual antigens also showed distinct diagnostic properties, with B6R providing the best overall discrimination, A35R showing highest sensitivity, and M1R demonstrating highest specificity.
Why it matters
This simplified testing approach could enable more practical and cost-effective surveillance of mpox exposure at the population level and better evaluation of vaccine effectiveness. The two-antigen test offers a scalable alternative to complex multiplex assays, making widespread serological monitoring more feasible for public health authorities.
Understand the Science
⚠️ Preprint – Noch nicht peer-reviewed
Dieser Artikel wurde noch nicht von unabhängigen Experten begutachtet. Die Ergebnisse sind vorläufig und sollten mit Vorsicht interpretiert werden.
Reliable serological tools are needed to measure mpox virus (MPXV) exposure, evaluate vaccine-induced immunity, and support population-level surveillance. Using a previously established six-antigen serological reference framework, in which seropositivity was defined as reactivity to [≥]4 of 6 MPXV antigens, we evaluated the diagnostic performance of individual antigens and all 15 pairwise combinations. B6R demonstrated the highest overall individual discriminatory performance, whereas A35R showed maximal sensitivity and M1R the highest specificity. The A35R+B6R combination most closely approximated the full multiplex assay (AUC 0.93), supporting simplified, scalable MPXV serological assays for surveillance and vaccine evaluation.